
CALLAN JMB INC.
92
Recent developments include a significant manufacturing and commercialization agreement with Attune, contract extensions with the City of Chicago, formation of a joint venture with Revival Health, IPO completion, executive appointments, and insider share purchases.
- Callan JMB signed a manufacturing oversight, federal deployment, and commercialization agreement with Attune for approximately $50 to $75 million in total revenue [N1].
- The company posted a wider loss in fiscal Q2 as reported in August 2025 [N2].
- Callan JMB secured a six-month contract extension with the City of Chicago, increasing total funding to $9.1 million [N3].
- Formed a joint venture with Revival Health to enhance U.S. healthcare logistics and supply chain solutions [N4].
- Completed IPO in May 2025 with gross proceeds of approximately $5.7 million [N5].
- Appointed Christopher Shields as Senior VP of Emergency Preparedness & Response to expand operations [N6].
- Insider purchases reported: Chief Medical Officer bought 25,000 shares [N7]; CEO and President bought 25,625 shares [N8].
Callan JMB Inc. operates as a vertically integrated logistics and fulfillment provider focused on thermal management logistics solutions for the life sciences sector. Its offerings include specialty temperature-regulating reusable packaging, emergency preparedness and response services, fulfillment services, and advanced monitoring technology (Sentry) that tracks temperature, humidity, and location to maintain product integrity. The company serves a diversified customer base including government agencies and Fortune 500 firms, emphasizing environmental sustainability and regulatory compliance. It completed its IPO in 2025 and is pursuing growth opportunities in adjacent markets such as GLP-1 drug transport and high-end food packaging.
Callan JMB Inc. is a vertically integrated logistics and fulfillment company specializing in thermal management solutions for the life sciences industry. The company provides proprietary packaging, advanced monitoring technology, and emergency response services to ensure the integrity of temperature-sensitive products. It completed its IPO in early 2025, raising approximately $5.7 million. Recent developments include a significant manufacturing and commercialization agreement with Attune, contract extensions with the City of Chicago, and a joint venture with Revival Health. Financially, as of September 30, 2026, the company reported $1.15 million in revenue and a net loss of $2.64 million, with liquidity ratios indicating a current ratio of 0.91 and cash ratio of 0.51. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
The company leverages its proprietary technology and extensive experience to serve a growing market for temperature-sensitive logistics in life sciences. Its recent manufacturing and commercialization agreement with Attune and joint venture with Revival Health demonstrate strategic partnerships that could enhance service offerings and revenue streams. Expansion into adjacent markets such as GLP-1 drug transport and high-end food packaging could diversify its customer base. Insider purchases and executive appointments indicate management confidence and operational expansion.
Callan JMB operates in a competitive environment with numerous local, regional, and national firms, some of which may offer overlapping services. The company reported a net loss and negative earnings per share in the latest quarter, with liquidity ratios below 1.0, indicating potential short-term financial constraints. Heavy reliance on a few large customers (top three accounting for 79% of revenue) may pose concentration risk. Regulatory compliance costs and environmental liabilities could increase unexpectedly. Market expansion efforts may face execution challenges and competitive pressures.
Callan JMB's competitive advantages stem from its vertically integrated logistics system combining proprietary packaging, advanced predictive technology, and specialized cold chain expertise tailored to highly regulated life sciences products. Its long-standing relationships with government agencies and Fortune 500 companies, comprehensive service offerings including emergency response, and commitment to environmental sustainability through reusable packaging create barriers to entry. The company's specialized technology and regulatory compliance capabilities further differentiate it from competitors who offer narrower or less integrated solutions.
• Customer Concentration Risk: Approximately 79% of revenue is derived from the top three customers, which may expose the company to significant revenue fluctuations if any major customer reduces business.
• Financial Performance and Liquidity: The company reported a net loss of $2.64 million and negative EPS of $0.44 for the nine months ended September 30, 2026, with a current ratio of 0.91 indicating liquidity below the ideal threshold.
• Regulatory and Compliance Risks: Callan JMB is subject to extensive federal, state, and local regulations related to logistics, packaging, and environmental standards, which may result in costly compliance requirements or penalties.
• Competitive Landscape: The company faces competition from numerous local, regional, and national firms, some of which may offer specialized or overlapping services, potentially impacting market share and pricing.
Business trends: Expansion into adjacent markets such as GLP-1 drug transport and high-end food packaging alongside growth in emergency response and thermal logistics services.
Execution milestones: Completion of IPO, securing significant contracts including with Attune and City of Chicago, formation of joint ventures, and key executive appointments.
Key risks: Customer concentration, ongoing net losses, regulatory compliance costs, and competitive pressures in a fragmented logistics market.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Callan JMB Inc. is a vertically integrated logistics and fulfillment company specializing in thermal management logistics solutions for the life sciences industry, using proprietary packaging, IT, and cold chain logistics expertise to ensure product integrity and environmental responsibility [S1].
- The company offers a comprehensive system combining advanced predictive technology to guarantee safety, effectiveness, and potency of temperature-sensitive products such as personalized medicine, cell therapies, vaccines, diagnostic materials, and bio-pharmaceuticals [S1].
- Callan JMB's service offerings include emergency preparedness and response, specialty temperature-regulating reusable packaging, fulfillment services, and advanced monitoring technology called Sentry, which tracks temperature, humidity, and location to ensure product integrity during transit [S1].
- The company emphasizes environmental sustainability through reusable packaging and a leasing model that reduces waste and costs compared to traditional single-use packaging [S1].
- Callan JMB serves a diversified customer base including Fortune 500 firms, government agencies such as the City of Chicago, NATO, and the UN, with its top three customers accounting for approximately 79% of revenue as of December 31, 2025 [S1].
- The company has a history of over 17 years in emergency response logistics and aims to expand into additional markets such as GLP-1 drug transport, compounding pharmacies, and high-end food packaging, leveraging its Sentry monitoring system [S1].
- Callan JMB completed its IPO in early 2025, raising approximately $5.7 million in gross proceeds [N5][N9].
- Recent contract developments include a six-month extension with the City of Chicago increasing total funding to $9.1 million and a manufacturing oversight and commercialization agreement with Attune for approximately $50 to $75 million in total revenue [N3][N1].
- The company formed a joint venture with Revival Health to enhance U.S. healthcare logistics and supply chain solutions [N4].
- Executive appointments include Christopher Shields as Senior VP of Emergency Preparedness & Response to expand operations [N6].
- Insider purchases were reported by the CEO and President (25,625 shares) and the Chief Medical Officer (25,000 shares) in early 2025 [N8][N7].
- Financial snapshot as of September 30, 2026, shows cash and equivalents of $1.78 million, current assets of $3.16 million, current liabilities of $3.47 million, resulting in a current ratio of 0.91 and cash ratio of 0.51 [S2].
- Revenue for the nine months ended September 30, 2026, was approximately $1.15 million, with a net loss of $2.64 million and basic and diluted EPS of -$0.44 per share [S2].
- The company operates with a small workforce of 20 employees, including 18 full-time and 2 part-time or seasonal, supplemented by independent contractors [S1].
- Callan JMB is subject to extensive regulatory compliance requirements including FDA, USDA, and state licenses relevant to its logistics and packaging operations in the life sciences sector [S1].
Generated 2026-11-17
- S1 | 2026-03-31 | 10-K
- S2 | 2026-11-13 | 10-Q
- N1 | 2026-01-15 | www.globenewswire.com | Callan JMB Signs Manufacturing Oversight, Federal Deployment, and Commercialization Agreement of Multi-Asset Therapeutic Pipeline with Attune for Approximately $50 to $75 Million in Total Revenue | https://www.globenewswire.com/news-release/2026/01/15/3219570/0/en/Callan-JMB-Signs-Manufacturing-Oversight-Federal-Deployment-and-Commercialization-Agreement-of-Multi-Asset-Therapeutic-Pipeline-with-Attune-for-Approximately-50-to-75-Million-in-To.html
- N2 | 2025-08-14 | www.nasdaq.com | Callan Jmb Posts Wider Loss in Fiscal Q2 | https://www.nasdaq.com/articles/callan-jmb-posts-wider-loss-fiscal-q2
- N3 | 2025-07-17 | www.nasdaq.com | Callan JMB Inc. Secures Six-Month Contract Extension with City of Chicago, Increasing Total Funding to $9.1 Million | https://www.nasdaq.com/articles/callan-jmb-inc-secures-six-month-contract-extension-city-chicago-increasing-total-funding
- N4 | 2025-05-21 | www.nasdaq.com | Callan JMB and Revival Health Form Joint Venture to Enhance U.S. Healthcare Logistics and Supply Chain Solutions | https://www.nasdaq.com/articles/callan-jmb-and-revival-health-form-joint-venture-enhance-us-healthcare-logistics-and
- N5 | 2025-05-15 | www.nasdaq.com | Callan JMB Inc. Completes IPO with Gross Proceeds of Approximately $5.7 Million and Provides Business Update | https://www.nasdaq.com/articles/callan-jmb-inc-completes-ipo-gross-proceeds-approximately-57-million-and-provides-business
- N6 | 2025-04-25 | www.nasdaq.com | Callan JMB Inc. Appoints Christopher Shields as Senior VP of Emergency Preparedness & Response to Expand Operations | https://www.nasdaq.com/articles/callan-jmb-inc-appoints-christopher-shields-senior-vp-emergency-preparedness-response
- N7 | 2025-04-03 | www.nasdaq.com | Insider Purchase: Chief Medical Officer of $CJMB Buys 25,000 Shares | https://www.nasdaq.com/articles/insider-purchase-chief-medical-officer-cjmb-buys-25000-shares
- N8 | 2025-03-14 | www.nasdaq.com | Insider Purchase: CEO and President of $CJMB Buys 25,625 Shares | https://www.nasdaq.com/articles/insider-purchase-ceo-and-president-cjmb-buys-25625-shares
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


